Stay updated on Pembrolizumab for Cancer of Unknown Primary Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Cancer of Unknown Primary Clinical Trial page.
Latest updates to the Pembrolizumab for Cancer of Unknown Primary Clinical Trial page
- Check2 days agoChange DetectedA 'Last known status' entry was added, listing Imperial College London with the date 2023-12 and a verification status of Unknown.SummaryDifference0.4%
- Check9 days agoChange DetectedAdded Revision: v3.3.3; removed HHS Vulnerability Disclosure and Revision: v3.3.2.SummaryDifference0.1%
- Check24 days agoNo Change Detected
- Check45 days agoChange DetectedRevision: v3.3.2 was applied to the page, replacing v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check52 days agoChange DetectedRemoved the government funding/operating status notice from the page. Core trial information remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
- Check67 days agoChange DetectedNo substantive changes detected in the core study content; updates appear to be minor formatting or copy edits. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%
- Check95 days agoChange DetectedUpdate includes a critical operating status notice and a new software version (v3.2.0), indicating updated deployment with potential service impact; previous version reference (v3.1.0) was removed.SummaryDifference3%
Stay in the know with updates to Pembrolizumab for Cancer of Unknown Primary Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Cancer of Unknown Primary Clinical Trial page.